Contact the Editorial Desk

Editorial correspondence

Assent Peptides welcomes correspondence on the research record: a citation quoted inaccurately, a regulatory reference that has gone out of date, or a peer-reviewed study about retatrutide or tirzepatide that should be added to the references page. Corrections that improve accuracy are the most useful messages this desk receives, and they are read carefully.

The most actionable notes specify: the page they refer to, the exact passage in question, and the supporting citation — a DOI or PubMed ID wherever possible. That lets us verify a proposed change against the source directly.

Editorial mailbox: editors@assentpeptides.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, some things fall outside what this site can address. Assent Peptides is a literature digest, not a clinic or vendor, so it cannot:

• Advise on, recommend, or comment on human use of any compound discussed here.
• Suggest a dose, schedule, or route of administration for any individual.
• Diagnose a condition or judge whether a research finding applies to a specific person.
• Sell, source, recommend, or help locate any compound from any supplier.
• Answer questions from athletes subject to anti-doping rules about compound use.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed; the mailbox is monitored intermittently.